Naproxen

Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers. It is grouped under the following drug class(es): Cyclooxygenase‑1 (COX‑1) Inhibitors, Cyclooxygenase‑2 (COX‑2) Inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAID). Its therapeutic use is listed as analgesics, anti-inflammatories, antipyretics, antirheumatic agents and osteoarthritis agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include (S)-Naproxen, Naprosyn, Naproxene and Aleve. Its PubChem CID is 156391.

CAS No 22204-53-1
Molecular Formula C14H14O3
Molecular Weight 230.26 g/mol
Synonyms (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid

Frequently Asked Questions